Portfoliotracker

Ryvu Therapeutics S.A.

RVU.WA · WARSAW · Healthcare Biotechnology 0/100 E

17,02 PLN
▼ −0,58 (−3,30 %)
Trading
Price as of 17. 11. 15:09, fetched 17. 11. 15:25
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score0 / 100 Market cap383 mil. PLN P/E– Forward P/E7,4 P/S6,2 P/B13,5 EV/EBITDA– Dividend yield– FCF yield-22,24 % EPS-3,00 PLN Net margin-81,0 % Return on equity-39,5 % Beta0,36 Debt / equity3,25
52-week range 13,64 to 31,90
3-month average volume0,0 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial for the treatment of diffuse large b-cell lymphoma and acute myeloid leukemia. In addition, the company's early pipeline candidates include candidates in the areas of kinases, synthetic lethality, immunometabolism, and immuno-oncology. It has collaborations with BioNTech SE to advance small molecule programs to target immune modulation in cancer and other disease areas; Exelixis Inc. for the development of targeted therapies based on Ryvu's STING agonist technology. The company was formerly known as Selvita S.A. and changed its name to Ryvu Therapeutics S.A. in October 2019. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.

Website
ryvu.com
Employees
228
Country
Poland
Data since
14. 7. 2011

Explore further

Similar companies SLV.WAJSW.WACTX.WAALE.WA

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account